On October 11, 2022 the Board of Directors of CymaBay Therapeutics, Inc. appointed Charles McWherter, Ph.D. as President of Research and Development of CymaBay, effective as of November 1, 2022. Charles McWherter, Ph.D., age 67, has served as CymaBay's Senior Vice President and Chief Scientific Officer since 2013. From 2007 to 2013, he served as CymaBay's Senior Vice President, Research and Preclinical Development.

From 2003 to 2007, he served as Vice President and head of the cardiovascular therapeutics areas of Pfizer Inc., a biopharmaceutical company. From 2001 to 2003, Dr. McWherter served as Vice President of Drug Discovery at Sugen, Inc., a biopharmaceutical company acquired by Pfizer Inc. in 2003. Dr. McWherter obtained his Ph.D. from Cornell University.